GAO Backs Prescription Pseudoephedrine Approach
This article was originally published in The Tan Sheet
Executive Summary
Senator Feinstein says PSE products should be available only by prescription nationwide. A GAO report supports “an expansion of prescription-only laws in the fight to combat the serious epidemic of meth production,” she says.
You may also be interested in...
Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
NPLEx Pays Dividends In Stopping Multi-State PSE Purchases
The largest amount of NPLEx-stopped sales was in Texas – 209,000 grams or 82,000 boxes. “People who don’t know the tracking system is in effect are still trying to purchase over the legal limit across state lines,” says National Association of Drug Diversion Investigators Executive Director Charles Cichon.